Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, the Netherlands.
Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands.
Int J Colorectal Dis. 2022 Sep;37(9):2013-2020. doi: 10.1007/s00384-022-04209-4. Epub 2022 Aug 19.
The COVID-19 pandemic had a major impact on the health services worldwide. We aimed to investigate the impact of the pandemic on colorectal cancer (CRC) care in the Netherlands in 2020.
CRC patients, diagnosed in 2018-2020 in the Netherlands, were selected from the Netherlands Cancer Registry (NCR). The year 2020 was divided in four periods reflecting COVID-19 developments in the Netherlands (pre-COVID, 1st peak, recovery period, 2nd peak) and compared with the same periods in 2018/2019. Patient characteristics and treatment were compared using the Chi-squared test. Median time between diagnosis and treatment, and between (neo)adjuvant therapy and surgery were analyzed by the Mann-Whitney U test.
In total, 38,021 CRC patients were diagnosed in 2018/2019 (n = 26,816) and 2020 (n = 11,205). Median time between diagnosis and initial treatment decreased on average 4 days and median time between neoadjuvant radiotherapy and surgery in clinical stage II or III rectal cancer patients increased on average 34 days during the three COVID-19 periods compared to the same periods of 2018/2019. The proportion of colon cancer patients that underwent elective surgery significantly decreased with 3.0% during the 1st peak. No differences were found in the proportion of patients who received (neo)adjuvant therapy, systemic therapy, or no anti-cancer treatment.
Only minor changes in the care for CRC patients occurred during the COVID-19 pandemic, mostly during the 1 peak. In conclusion, the impact on CRC care in the Netherlands was found to be limited. However, long-term effects cannot be precluded.
COVID-19 大流行对全球卫生服务系统产生了重大影响。我们旨在研究 2020 年 COVID-19 对荷兰结直肠癌(CRC)治疗的影响。
从荷兰癌症登记处(NCR)中选择 2018-2020 年在荷兰诊断为 CRC 的患者。2020 年分为四个时期,反映了荷兰 COVID-19 的发展情况(COVID-19 之前、第一高峰、恢复期、第二高峰),并与 2018/2019 年同期进行了比较。使用卡方检验比较患者特征和治疗方法。使用 Mann-Whitney U 检验分析诊断和治疗之间以及(新)辅助治疗和手术之间的中位时间。
2018/2019 年(n=26816)和 2020 年(n=11205)共诊断出 38021 例 CRC 患者。与 2018/2019 年同期相比,三个 COVID-19 期间,诊断与初始治疗之间的平均时间缩短了 4 天,临床分期 II 或 III 期直肠癌患者中,新辅助放疗与手术之间的平均时间增加了 34 天。与 2018/2019 年同期相比,接受择期手术的结肠癌患者比例在第一高峰时显著下降了 3.0%。接受(新)辅助治疗、系统治疗或无抗癌治疗的患者比例无差异。
COVID-19 大流行期间,CRC 患者的治疗仅发生了微小变化,主要发生在第一高峰期间。总之,荷兰 CRC 治疗的影响有限。但是,不能排除长期影响。